Title
Direct determination of pyrazinamide (PZA) susceptibility by sputum microscopic observation drug susceptibility (MODS) culture at neutral pH: The MODS-PZA assay
Date Issued
01 May 2020
Access level
open access
Resource Type
journal article
Publisher(s)
American Society for Microbiology
Abstract
Pyrazinamide (PZA) is considered the pivot drug in all tuberculosis treatment regimens due to its particular action on the persistent forms of Mycobacterium tuberculosis. However, no drug susceptibility test (DST) is considered sufficiently reliable for routine application. Although molecular tests are endorsed, their application is limited to known PZA resistance associated mutations. Microbiological DSTs for PZA have been restricted by technical limitations, especially the necessity for an acidic pH. Here, for the first time, MODS culture at neutral pH was evaluated using high PZA concentrations (400 and 800 _g/ml) to determine PZA susceptibility directly from sputum samples. Sputum samples were cultured with PZA for up to 21 days at 37°C. Plate reading was performed at two time points: R1 (mean, 10 days) and R2 (mean, 13 days) for each PZA concentration. A consensus reference test, composed of MGIT-PZA, pncA sequencing, and the classic Wayne test, was used. A total of 182 samples were evaluated. The sensitivity and specificity for 400 μg/ml ranged from 76.9 to 89.7 and from 93.0 to 97.9%, respectively, and for 800 μg/ml ranged from 71.8 to 82.1 and from 95.8 to 98.6%, respectively. Compared to MGITPZA, our test showed a similar turnaround time (medians of 10 and 12 days for PZAsensitive and -resistant isolates, respectively). In conclusion, MODS-PZA is presented as a fast, simple, and low-cost DST that could complement the MODS assay to evaluate resistance to the principal first-line antituberculosis drugs. Further optimization of test conditions would be useful in order to increase its performance.
Volume
58
Issue
5
Language
English
OCDE Knowledge area
Sistema respiratorio Enfermedades infecciosas
Scopus EID
2-s2.0-85084027576
PubMed ID
Source
Journal of Clinical Microbiology
ISSN of the container
00951137
Sponsor(s)
This study was funded by the Wellcome Trust Intermediate Fellowship (099805/Z/ 112/Z). This study was also partially funded by Grand Challenge Canada (0687-01-10) and by FONDECyT-Peru (037-22014). D.E.K. is supported by an MRC Clinical Research Training Fellowship. All authors declare that they have no conflicts of interest.
Sources of information: Directorio de Producción Científica Scopus